BMY
Bristol-Myers Squibb Company
October 14, 2026 · intraday
- Rarity
- 1.25
- Peak move
- +4.72%
- Float cap
- $115.1B
Bristol-Myers Squibb Company is a biopharmaceutical company that discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines for serious diseases. Its therapies target oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. Products are sold worldwide, primarily to wholesalers, distributors, specialty pharmacies, and, to a lesser extent, retailers, hospitals, clinics, government agencies, and patients.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
9 events · 0 from SEC or newswire · 0 timed with the movepeer_disclosureContineum Therapeutics fell sharply after Bristol-Myers Squibb released its ALOFT-IPF Phase 3 data for admilparant, which targets the same LPA1 program.
- Key event
analyst_ratingWells Fargo lowered its price target on Bristol-Myers Squibb to $60 from $65 while maintaining an Equal Weight rating, citing Eliquis loss of exclusivity in major EU markets in mid-November and questions on admilparant efficacy and safety.
analyst_ratingJefferies adjusted its price target on Bristol-Myers Squibb to $76 from $73, reiterating a Neutral rating.
analyst_ratingSanford C. Bernstein reiterated a Market Perform rating and $61.00 price target on Bristol-Myers Squibb following the company's admilparant ALOFT-IPF data, noting the 60 mg dose succeeded while the 120 mg dose did not.
- Key event
patent_cliffBristol-Myers Squibb management said Eliquis will lose market exclusivity in mid-November 2026 in some major European Union markets, with a rapid sales decline expected afterward, while reaffirming current Eliquis guidance.
- Key event
analyst_ratingMorgan Stanley analyst Terence Flynn maintained a Sell rating on Bristol-Myers Squibb with an unchanged $41 price target, citing modest clinical benefit from admilparant's Phase 3 data and an inverted dose-response.
clinical_readoutBristol Myers Squibb reported positive Phase 3 results for RYZ101 in gastroenteropancreatic neuroendocrine tumours, with the study meeting its primary endpoint, alongside the admilparant IPF readout.
clinical_readoutBristol Myers Squibb reported that its Phase 3 ALOFT-IPF trial of admilparant met its primary endpoint, with the 60 mg twice-daily dose showing a statistically significant improvement in forced vital capacity at Week 52 versus placebo while the 120 mg dose did not reach significance.
product_launchBristol Myers Squibb and the Saudi Schizophrenia Association 'Ehtiwaa' collaborated on the 'Small Wins' initiative, with more than 70 personalized toolkits assembled by BMS employees to support people living with schizophrenia in Saudi Arabia.